









## Humber Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on December 2023

### Classification of products:

Status	Description
 <b>GREEN</b>	Medicines suitable for routine use within primary care and Secondary care. May be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies
 <b>AMB 1</b>	Specialist recommendation: These medicines are considered suitable for GP prescribing following specialist recommendation or via an APC approved prescribing guideline.
 <b>AMB 2</b>	Specialist initiation: These medicines are considered suitable for GP prescribing following specialist initiation, including titration of dose and assessment of efficacy. These medicines may also have an APC approved guideline to aid GPs in further prescribing.
 <b>AMB SCP</b>	AMBER SHARE CARE PROTOCOL- Specialist initiation with ongoing monitoring: Medicines that must be initiated by a specialist, and which require significant monitoring on an ongoing basis. Full agreement to share the care of each specific patient must be reached under the shared care protocol which must be provided to the GP. If a commissioned shared care is not available in CCG/place then these drugs must be treated as red drug (hospital only).
 <b>RED</b>	Red-Hospital initiation and continuation only
 <b>GREY</b>	GREY- NON FORMULARY (As agreed by Area Prescribing Committee)
 <b>PURPLE</b>	To be supplied from the appropriate commissioned provider.
 <b>NR</b>	Not routinely commissioned

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>1) Requests deferred from previous meetings</b>				
Nil this month				
<b>2) New Requests</b>				
Rimegepant	<b>AMB 2</b>			HUTH – application for TAs 906/TA919, classified for only TA906
Revamil Honey dressing	<b>RED</b>			HUTH only
<b>3) New formulations &amp; extensions to use</b>				

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Nil this month				
<b>4) Products considered by NICE</b>				
<a href="#">TA915: Pegunigalsidase alfa for treating Fabry disease</a>	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner. Neither HUTH or NLAG NHSE centres
<a href="#">TA916: Bimekizumab for treating active psoriatic arthritis</a>			RED	ICS is the responsible commissioner. Deferred awaiting pathway
<a href="#">TA917: Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable</a>	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<a href="#">TA918: Bimekizumab for treating axial spondyloarthritis</a>			RED	The formulary will reflect the TAG – ICS is the responsible commissioner.
<a href="#">TA919: Rimegepant for treating migraine</a>			<input checked="" type="checkbox"/>	ICS is the responsible commissioner. Deferred awaiting pathway
<a href="#">TA920: Tofacitinib for treating active ankylosing spondylitis</a>			RED	Deferred awaiting pathway
<a href="#">TA921: Ruxolitinib for treating polycythaemia vera</a>	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>5) Appeals against earlier decisions by the APC</b>				
None				
<b>6) Miscellaneous formulary decisions by the APC</b>				
Nil this month				

The following guidelines were presented to and approved at the December 2023 meeting of the APC:

- Erectile dysfunction following prostatectomy

The following Drug information leaflets were presented to and approved at the December 2023 meeting of the APC:

- Nil this month

The following shared care guidelines were presented to and approved at the December 2023 meeting of the APC:

- Nil this month

Other documents presented to and approved at the December 2023 meeting of the APC:

- Infliximab accelerated and escalated dose regimens